☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
gilead
US FDA Grants Accelerated Approval to Gilead’s Livdelzi (Seladelpar) to Treat Primary Biliary Cholangitis (PBC)
August 16, 2024
Gilead Reports Data from the P-III (ASSURE) Trial of Seladelpar for Treating Primary Biliary Cholangitis
June 5, 2024
The US FDA Approves the Label Update of Gilead’s Biktarvy for Pregnant Adults with HIV
April 29, 2024
Gilead Reports the US FDA’s Approval of sNDA for Vemlidy to Treat Hepatitis B Virus (HBV) Infection
April 1, 2024
Gilead and Xilio Therapeutics Join Forces to Develop XTX301 for the Treatment of Cancers
March 29, 2024
Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV
March 7, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.